Company profile: Cisiv
1.1 - Company Overview
Company description
- Provider of real-world data technology for pharmaceutical companies, including Baseline Plus for late-phase research with customizable workflows; a 21 CFR Part 11-compliant eConsent module integrated with Baseline Plus; patient apps for PROs, COAs, and eDiaries; electronic tools for observational studies; support for post-approval safety studies (PASS); and systems for retrospective chart reviews.
Products and services
- EConsent Module: A 21 CFR Part 11-compliant component that enables patients to remotely consent to study participation, integrating seamlessly with Baseline Plus features for compliant electronic consent workflows
- Baseline Plus: A customizable platform for late phase research that delivers collection and analysis of real-world data using configurable tools and workflows tailored to study requirements
- Patient App: An iOS- and Android-compatible mobile product that delivers Patient Reported Outcomes, Clinical Outcome Assessments, and eDiaries to capture patient-level data during studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cisiv
FlowJo
HQ: United States
Website
- Description: Provider of life sciences software for flow cytometry and single-cell analysis, offering FlowJo for viewing and analyzing flow cytometric data (sample management, gating, statistics, graphical layouts), BD Research Cloud for secure cloud storage, sharing and collaboration with integration to analysis software, and SeqGeq for single-cell RNA sequencing (scRNA-seq) data analysis and visualization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FlowJo company profile →
NiKang Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule oncology therapeutics, developing NKT2152, a HIF2α inhibitor in Phase 1/2 for clear cell renal cell carcinoma and other solid tumors; NKT3447, a reversible ATP-competitive CDK2 inhibitor in Phase 1 for solid tumors; KRAS G12D mutation inhibitors; and a SHP2 inhibitor being clinically evaluated by Erasca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NiKang Therapeutics company profile →
Neuron23
HQ: United States
Website
- Description: Provider of drug development programs for neurological and inflammatory diseases, including Parkinson's and Alzheimer's. Pipeline includes NEU-723, a brain-penetrant LRRK2 inhibitor in Phase 1 for Parkinson's; NEU-411, a follow-on LRRK2 inhibitor for Parkinson's expected to enter clinical trials in 2023; and TYK2 programs targeting systemic inflammation, neuroinflammation and MS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuron23 company profile →
Qualtrax
HQ: United States
Website
- Description: Provider of intranet-based quality and document control solutions supporting regulatory requirements in regulated industries. Offerings include Ideagen Quality Management for document control, workflow automation, and risk management, and specialized Food & Beverage editions focused on supplier management, risk assessment, and compliance with food safety standards. Based in Christiansburg, Virginia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qualtrax company profile →
GRO Biosciences
HQ: United States
Website
- Description: Provider of protein therapeutics technology leveraging Genomically Recoded Organisms to produce non-standard amino acid proteins. Offers the GRO Platform to expand the amino acid alphabet; a Biofoundry integrating computational design and robotics; DuraLogic chemistry to enhance protein structure and duration; and ProGly to modulate immune responses, aiming to treat autoimmunity and reduce anti-drug antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GRO Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cisiv
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cisiv
2.2 - Growth funds investing in similar companies to Cisiv
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cisiv
4.2 - Public trading comparable groups for Cisiv
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →